vs

Side-by-side financial comparison of Arcturus Therapeutics Holdings Inc. (ARCT) and FingerMotion, Inc. (FNGR). Click either name above to swap in a different company.

Arcturus Therapeutics Holdings Inc. is the larger business by last-quarter revenue ($7.2M vs $5.8M, roughly 1.2× FingerMotion, Inc.). On growth, FingerMotion, Inc. posted the faster year-over-year revenue change (-32.1% vs -68.4%). FingerMotion, Inc. produced more free cash flow last quarter ($-566.7K vs $-74.5M). Over the past eight quarters, FingerMotion, Inc.'s revenue compounded faster (-15.9% CAGR vs -56.5%).

Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA (siRNA), messenger RNA (mRNA), gene editing RNA, DNA, antisense oligonucleotides, and microRNA.

Leap Motion, Inc. was an American company, active from 2010 to 2019, that manufactured and marketed a computer hardware sensor device. The device supports hand and finger motions as input, analogous to a mouse, but requires no hand contact or touching. In 2016, the company released new software designed for hand tracking in virtual reality. The company was sold to the British company Ultrahaptics in 2019, which rebranded the two companies under the new name Ultraleap.

ARCT vs FNGR — Head-to-Head

Bigger by revenue
ARCT
ARCT
1.2× larger
ARCT
$7.2M
$5.8M
FNGR
Growing faster (revenue YoY)
FNGR
FNGR
+36.3% gap
FNGR
-32.1%
-68.4%
ARCT
More free cash flow
FNGR
FNGR
$73.9M more FCF
FNGR
$-566.7K
$-74.5M
ARCT
Faster 2-yr revenue CAGR
FNGR
FNGR
Annualised
FNGR
-15.9%
-56.5%
ARCT

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
ARCT
ARCT
FNGR
FNGR
Revenue
$7.2M
$5.8M
Net Profit
$-1.7M
Gross Margin
4.5%
Operating Margin
-29.4%
Net Margin
-28.8%
Revenue YoY
-68.4%
-32.1%
Net Profit YoY
3.1%
-0.6%
EPS (diluted)
$-0.03

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARCT
ARCT
FNGR
FNGR
Q4 25
$7.2M
$5.8M
Q3 25
$17.2M
$8.6M
Q2 25
$28.3M
$8.5M
Q1 25
$29.4M
$10.2M
Q4 24
$22.8M
$8.5M
Q3 24
$41.7M
$8.5M
Q2 24
$49.9M
$8.4M
Q1 24
$38.0M
$8.2M
Net Profit
ARCT
ARCT
FNGR
FNGR
Q4 25
$-1.7M
Q3 25
$-13.4M
$-1.5M
Q2 25
$-9.2M
$-2.0M
Q1 25
$-14.1M
$-107.9K
Q4 24
$-30.0M
$-1.7M
Q3 24
$-6.9M
$-1.7M
Q2 24
$-17.2M
$-1.7M
Q1 24
$-26.8M
$-467.6K
Gross Margin
ARCT
ARCT
FNGR
FNGR
Q4 25
4.5%
Q3 25
0.4%
Q2 25
1.8%
Q1 25
13.1%
Q4 24
5.2%
Q3 24
3.6%
Q2 24
8.1%
Q1 24
8.8%
Operating Margin
ARCT
ARCT
FNGR
FNGR
Q4 25
-29.4%
Q3 25
-96.3%
-17.2%
Q2 25
-41.0%
-23.5%
Q1 25
-57.3%
-9.4%
Q4 24
-146.7%
-18.9%
Q3 24
-25.8%
-20.0%
Q2 24
-42.4%
-20.0%
Q1 24
-80.0%
-5.8%
Net Margin
ARCT
ARCT
FNGR
FNGR
Q4 25
-28.8%
Q3 25
-78.4%
-17.8%
Q2 25
-32.4%
-23.7%
Q1 25
-47.9%
-1.1%
Q4 24
-131.8%
-19.5%
Q3 24
-16.6%
-20.0%
Q2 24
-34.5%
-19.8%
Q1 24
-70.5%
-5.7%
EPS (diluted)
ARCT
ARCT
FNGR
FNGR
Q4 25
$-0.03
Q3 25
$-0.49
$-0.03
Q2 25
$-0.34
$-0.04
Q1 25
$-0.52
$0.00
Q4 24
$-1.10
$-0.03
Q3 24
$-0.26
$-0.03
Q2 24
$-0.64
$-0.03
Q1 24
$-1.00
$-0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARCT
ARCT
FNGR
FNGR
Cash + ST InvestmentsLiquidity on hand
$230.9M
$24.2K
Total DebtLower is stronger
Stockholders' EquityBook value
$214.0M
$16.4M
Total Assets
$271.1M
$60.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARCT
ARCT
FNGR
FNGR
Q4 25
$230.9M
$24.2K
Q3 25
$180.4M
$221.8K
Q2 25
$196.5M
$2.9M
Q1 25
$216.9M
$1.1M
Q4 24
$237.0M
$164.6K
Q3 24
$237.2M
$810.3K
Q2 24
$260.3M
$1.1M
Q1 24
$288.4M
$1.5M
Stockholders' Equity
ARCT
ARCT
FNGR
FNGR
Q4 25
$214.0M
$16.4M
Q3 25
$224.6M
$15.1M
Q2 25
$231.1M
$16.2M
Q1 25
$233.8M
$13.7M
Q4 24
$241.0M
$9.6M
Q3 24
$261.9M
$9.9M
Q2 24
$258.6M
$10.9M
Q1 24
$264.0M
$11.7M
Total Assets
ARCT
ARCT
FNGR
FNGR
Q4 25
$271.1M
$60.1M
Q3 25
$282.3M
$51.9M
Q2 25
$309.3M
$55.7M
Q1 25
$331.8M
$48.8M
Q4 24
$344.1M
$31.9M
Q3 24
$370.7M
$30.2M
Q2 24
$388.6M
$26.3M
Q1 24
$418.8M
$18.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARCT
ARCT
FNGR
FNGR
Operating Cash FlowLast quarter
$-74.3M
$-548.4K
Free Cash FlowOCF − Capex
$-74.5M
$-566.7K
FCF MarginFCF / Revenue
-1035.2%
-9.8%
Capex IntensityCapex / Revenue
3.2%
0.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARCT
ARCT
FNGR
FNGR
Q4 25
$-74.3M
$-548.4K
Q3 25
$-17.2M
$-1.9M
Q2 25
$-5.8M
$-1.2M
Q1 25
$-35.1M
$-3.6M
Q4 24
$-284.0K
$-1.7M
Q3 24
$-23.8M
$-1.5M
Q2 24
$-30.1M
$-1.4M
Q1 24
$-5.6M
$-374.3K
Free Cash Flow
ARCT
ARCT
FNGR
FNGR
Q4 25
$-74.5M
$-566.7K
Q3 25
$-17.3M
Q2 25
$-1.2M
Q1 25
$-35.3M
Q4 24
$-1.7M
Q3 24
$-23.8M
Q2 24
$-30.5M
Q1 24
$-5.8M
$-374.3K
FCF Margin
ARCT
ARCT
FNGR
FNGR
Q4 25
-1035.2%
-9.8%
Q3 25
-101.1%
Q2 25
-14.3%
Q1 25
-120.1%
Q4 24
-19.7%
Q3 24
-57.2%
Q2 24
-61.1%
Q1 24
-15.3%
-4.6%
Capex Intensity
ARCT
ARCT
FNGR
FNGR
Q4 25
3.2%
0.3%
Q3 25
1.1%
0.0%
Q2 25
0.0%
0.0%
Q1 25
0.5%
Q4 24
0.0%
0.0%
Q3 24
0.2%
Q2 24
0.7%
Q1 24
0.6%
0.0%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons